Hap Trading, LLC Anavex Life Sciences Corp. Call Options Transaction History

Hap Trading, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	SELL	$7.66 - $9.5 $29,874 - $37,050	-3,900 Reduced 23.78%	12,500 $101,000
Q1 2023 May 12, 2023	SELL	$8.32 - $11.75 $188,864 - $266,725	-22,700 Reduced 58.06%	16,400 $8,000
Q4 2022 Feb 14, 2023	SELL	$7.65 - $14.43 $13,770 - $25,974	-1,800 Reduced 4.4%	39,100 $33,000
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $92,560 - $133,744	-10,400 Reduced 20.27%	40,900 $71,000
Q2 2022 Aug 12, 2022	SELL	$7.31 - $12.84 $90,644 - $159,216	-12,400 Reduced 19.47%	51,300 $70,000
Q1 2022 May 12, 2022	BUY	$9.74 - $17.69 $417,846 - $758,901	42,900 Added 206.25%	63,700 $82,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $11,816 - $16,317	700 Added 3.48%	20,800 $31,000
Q3 2021 Nov 10, 2021	SELL	$16.82 - $25.75 $299,396 - $458,350	-17,800 Reduced 46.97%	20,100 $30,000
Q2 2021 Aug 11, 2021	BUY	$10.16 - $28.86 $4,064 - $11,544	400 Added 1.07%	37,900 $225,000
Q1 2021 May 14, 2021	BUY	$5.17 - $16.13 $83,237 - $259,692	16,100 Added 75.23%	37,500 $176,000
Q4 2020 Feb 16, 2021	BUY	$4.01 - $7.58 $29,674 - $56,092	7,400 Added 52.86%	21,400 $12,000
Q3 2020 Nov 13, 2020	BUY	$3.8 - $5.0 $53,200 - $70,000	14,000 New	14,000 $15,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $847M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.